Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase NA × Liver Neoplasms × durvalumab × Clear all

Phase

Phase 2 7 Phase 3 3 Phase 1 2 Phase NA 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 2 Small Cell Lung Carcinoma 1 Liver Neoplasms 1 Esophageal Squamous Cell Carcinoma 1 Endometrial Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Biliary Tract Neoplasms 1

Interventions

Radiofrequency Ablation 5 lenvatinib 4 Radiosurgery 4 Electroporation 4 Radiotherapy 3 Hepatectomy 3 sintilimab 2 perflutren 2 Proton Therapy 2 Patient Navigation 2 Nutritional Status 2 Magnetic Resonance Spectroscopy 2 Liver Transplantation 2 Injections 2 Exercise 2 Dextrins 2 Cryosurgery 2 Control Groups 2 Anesthesia, General 2 toripalimab 1 tislelizumab 1 seocalcitol 1 pembrolizumab 1 motexafin gadolinium 1 gadofosveset trisodium 1 gadobutrol 1 gadobenic acid 1 erythromycin propionate-N-acetylcysteinate 1 durvalumab 1 camrelizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04443322 2020-09-22

Dulect2020-1

RenJi Hospital

Phase NA Unknown

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡